Skip to main content
Erschienen in: Heart Failure Reviews 4/2022

08.10.2021

Histamine receptors in heart failure

verfasst von: Scott P. Levick

Erschienen in: Heart Failure Reviews | Ausgabe 4/2022

Einloggen, um Zugang zu erhalten

Abstract

The biogenic amine, histamine, is found predominantly in mast cells, as well as specific histaminergic neurons. Histamine exerts its many and varied actions via four G-protein-coupled receptors numbered one through four. Histamine has multiple effects on cardiac physiology, mainly via the histamine 1 and 2 receptors, which on a simplified level have opposing effects on heart rate, force of contraction, and coronary vasculature function. In heart failure, the actions of the histamine receptors are complex, the histamine 1 receptor appears to have detrimental actions predominantly in the coronary vasculature, while the histamine 2 receptor mediates adverse effects on cardiac remodeling via actions on cardiomyocytes, fibroblasts, and even endothelial cells. Conversely, there is growing evidence that the histamine 3 receptor exerts protective actions when activated. Little is known about the histamine 4 receptor in heart failure. Targeting histamine receptors as a therapeutic approach for heart failure is an important area of investigation given the over-the-counter access to many compounds targeting these receptors, and thus the relatively straight forward possibility of drug repurposing. In this review, we briefly describe histamine receptor signaling and the actions of each histamine receptor in normal cardiac physiology, before describing in more detail the known role of each histamine receptor in adverse cardiac remodeling and heart failure. This includes information from both clinical studies and experimental animal models. It is the goal of this review article to bring more focus to the possibility of targeting histamine receptors as therapy for heart failure.
Literatur
1.
Zurück zum Zitat Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE Jr, Colvin MM, Drazner MH, Filippatos G, Fonarow GC, Givertz MM et al (2016) 2016 ACC/AHA/HFSA focused update on new pharmacological therapy for heart failure: an update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. J Am Coll Cardiol 68(13):1476–1488PubMedCrossRef Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE Jr, Colvin MM, Drazner MH, Filippatos G, Fonarow GC, Givertz MM et al (2016) 2016 ACC/AHA/HFSA focused update on new pharmacological therapy for heart failure: an update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. J Am Coll Cardiol 68(13):1476–1488PubMedCrossRef
2.
Zurück zum Zitat Ferreira JP, Kraus S, Mitchell S, Perel P, Piñeiro D, Chioncel O, Colque R, de Boer RA, Gomez-Mesa JE, Grancelli H et al (2019) World Heart Federation Roadmap for heart failure. Glob Heart 14(3):197–214PubMedCrossRef Ferreira JP, Kraus S, Mitchell S, Perel P, Piñeiro D, Chioncel O, Colque R, de Boer RA, Gomez-Mesa JE, Grancelli H et al (2019) World Heart Federation Roadmap for heart failure. Glob Heart 14(3):197–214PubMedCrossRef
3.
Zurück zum Zitat Ambrosy AP, Fonarow GC, Butler J, Chioncel O, Greene SJ, Vaduganathan M, Nodari S, Lam CSP, Sato N, Shah AN et al (2014) The global health and economic burden of hospitalizations for heart failure: lessons learned from hospitalized heart failure registries. J Am Coll Cardiol 63(12):1123–1133PubMedCrossRef Ambrosy AP, Fonarow GC, Butler J, Chioncel O, Greene SJ, Vaduganathan M, Nodari S, Lam CSP, Sato N, Shah AN et al (2014) The global health and economic burden of hospitalizations for heart failure: lessons learned from hospitalized heart failure registries. J Am Coll Cardiol 63(12):1123–1133PubMedCrossRef
4.
Zurück zum Zitat Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JG, Coats AJ, Falk V, González-Juanatey JR, Harjola VP, Jankowska EA et al(2016) 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail 18(8):891–975 Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JG, Coats AJ, Falk V, González-Juanatey JR, Harjola VP, Jankowska EA et al(2016) 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail 18(8):891–975
5.
Zurück zum Zitat Virani SS, Alonso A, Benjamin EJ, Bittencourt MS, Callaway CW, Carson AP, Chamberlain AM, Chang AR, Cheng S, Delling FN et al (2020) Heart Disease and Stroke Statistics-2020 Update: a report From the American Heart Association. Circulation 141(9):e139–e596PubMedCrossRef Virani SS, Alonso A, Benjamin EJ, Bittencourt MS, Callaway CW, Carson AP, Chamberlain AM, Chang AR, Cheng S, Delling FN et al (2020) Heart Disease and Stroke Statistics-2020 Update: a report From the American Heart Association. Circulation 141(9):e139–e596PubMedCrossRef
6.
Zurück zum Zitat Nieto-Alamilla G, Márquez-Gómez R, García-Gálvez AM, Morales-Figueroa GE, Arias-Montaño JA (2016) The histamine H3 receptor: structure, pharmacology, and function. Mol Pharmacol 90(5):649–673PubMedCrossRef Nieto-Alamilla G, Márquez-Gómez R, García-Gálvez AM, Morales-Figueroa GE, Arias-Montaño JA (2016) The histamine H3 receptor: structure, pharmacology, and function. Mol Pharmacol 90(5):649–673PubMedCrossRef
7.
Zurück zum Zitat Ghamari N, Zarei O, Arias-Montaño JA, Reiner D, Dastmalchi S, Stark H, Hamzeh-Mivehroud M (2019) Histamine H(3) receptor antagonists/inverse agonists: where do they go? Pharmacol Ther 200:69–84PubMedCrossRef Ghamari N, Zarei O, Arias-Montaño JA, Reiner D, Dastmalchi S, Stark H, Hamzeh-Mivehroud M (2019) Histamine H(3) receptor antagonists/inverse agonists: where do they go? Pharmacol Ther 200:69–84PubMedCrossRef
8.
Zurück zum Zitat He G, Hu J, Li T, Ma X, Meng J, Jia M, Lu J, Ohtsu H, Chen Z, Luo X (2012) Arrhythmogenic effect of sympathetic histamine in mouse hearts subjected to acute ischemia. Mol Med (Cambridge, Mass) 18(1):1–9CrossRef He G, Hu J, Li T, Ma X, Meng J, Jia M, Lu J, Ohtsu H, Chen Z, Luo X (2012) Arrhythmogenic effect of sympathetic histamine in mouse hearts subjected to acute ischemia. Mol Med (Cambridge, Mass) 18(1):1–9CrossRef
9.
Zurück zum Zitat Marone G, de Crescenzo G, Adt M, Patella V, Arbustini E, Genovese A (1995) Immunological characterization and functional importance of human heart mast cells. Immunopharmacology 31(1):1–18PubMedCrossRef Marone G, de Crescenzo G, Adt M, Patella V, Arbustini E, Genovese A (1995) Immunological characterization and functional importance of human heart mast cells. Immunopharmacology 31(1):1–18PubMedCrossRef
10.
Zurück zum Zitat Marone G, de Crescenzo G, Florio G, Granata F, Dente V, Genovese A (1999) Immunological modulation of human cardiac mast cells. Neurochem Res 24(9):1195–1202PubMedCrossRef Marone G, de Crescenzo G, Florio G, Granata F, Dente V, Genovese A (1999) Immunological modulation of human cardiac mast cells. Neurochem Res 24(9):1195–1202PubMedCrossRef
11.
Zurück zum Zitat Patella V, de Crescenzo G, Ciccarelli A, Marino I, Adt M, Marone G (1995) Human heart mast cells: a definitive case of mast cell heterogeneity. Int Arch Allergy Immunol 106(4):386–393PubMedCrossRef Patella V, de Crescenzo G, Ciccarelli A, Marino I, Adt M, Marone G (1995) Human heart mast cells: a definitive case of mast cell heterogeneity. Int Arch Allergy Immunol 106(4):386–393PubMedCrossRef
12.
Zurück zum Zitat Batlle M, Perez-Villa F, Lazaro A, Garcia-Pras E, Ramirez J, Ortiz J, Orus J, Roque M, Heras M, Roig E (2007) Correlation between mast cell density and myocardial fibrosis in congestive heart failure patients. Transpl Proc 39(7):2347–2349CrossRef Batlle M, Perez-Villa F, Lazaro A, Garcia-Pras E, Ramirez J, Ortiz J, Orus J, Roque M, Heras M, Roig E (2007) Correlation between mast cell density and myocardial fibrosis in congestive heart failure patients. Transpl Proc 39(7):2347–2349CrossRef
13.
Zurück zum Zitat Brower GL, Chancey AL, Thanigaraj S, Matsubara BB, Janicki JS (2002) Cause and effect relationship between myocardial mast cell number and matrix metalloproteinase activity. Am J Physiol Heart Circ Physiol 283(2):H518-525PubMedCrossRef Brower GL, Chancey AL, Thanigaraj S, Matsubara BB, Janicki JS (2002) Cause and effect relationship between myocardial mast cell number and matrix metalloproteinase activity. Am J Physiol Heart Circ Physiol 283(2):H518-525PubMedCrossRef
14.
Zurück zum Zitat Forman MF, Brower GL, Janicki JS (2006) Rat cardiac mast cell maturation and differentiation following acute ventricular volume overload. Inflamm Res 55(10):408–415PubMedCrossRef Forman MF, Brower GL, Janicki JS (2006) Rat cardiac mast cell maturation and differentiation following acute ventricular volume overload. Inflamm Res 55(10):408–415PubMedCrossRef
15.
16.
Zurück zum Zitat Levick SP, McLarty JL, Murray DB, Freeman RM, Carver WE, Brower GL (2009) Cardiac mast cells mediate left ventricular fibrosis in the hypertensive rat heart. Hypertension (Dallas, Tex: 1979) 53(6):1041–1047 Levick SP, McLarty JL, Murray DB, Freeman RM, Carver WE, Brower GL (2009) Cardiac mast cells mediate left ventricular fibrosis in the hypertensive rat heart. Hypertension (Dallas, Tex: 1979) 53(6):1041–1047
17.
Zurück zum Zitat Li J, Lu H, Plante E, Melendez GC, Levick SP, Janicki JS (2012) Stem cell factor is responsible for the rapid response in mature mast cell density in the acutely stressed heart. J Mol Cell Cardiol 53(4):469–474PubMedPubMedCentralCrossRef Li J, Lu H, Plante E, Melendez GC, Levick SP, Janicki JS (2012) Stem cell factor is responsible for the rapid response in mature mast cell density in the acutely stressed heart. J Mol Cell Cardiol 53(4):469–474PubMedPubMedCentralCrossRef
18.
Zurück zum Zitat Melendez GC, Li J, Law BA, Janicki JS, Supowit SC, Levick SP (2011) Substance P induces adverse myocardial remodeling via a mechanism involving cardiac mast cells. Cardiovasc Res 92:420–429PubMedPubMedCentralCrossRef Melendez GC, Li J, Law BA, Janicki JS, Supowit SC, Levick SP (2011) Substance P induces adverse myocardial remodeling via a mechanism involving cardiac mast cells. Cardiovasc Res 92:420–429PubMedPubMedCentralCrossRef
19.
Zurück zum Zitat Morgan LG, Levick SP, Voloshenyuk TG, Murray DB, Forman MF, Brower GL, Janicki JS (2008) A novel technique for isolating functional mast cells from the heart. Inflamm Res 57:1–6CrossRef Morgan LG, Levick SP, Voloshenyuk TG, Murray DB, Forman MF, Brower GL, Janicki JS (2008) A novel technique for isolating functional mast cells from the heart. Inflamm Res 57:1–6CrossRef
20.
Zurück zum Zitat Widiapradja A, Manteufel EJ, Dehlin HM, Pena J, Goldspink PH, Sharma A, Kolb LL, Imig JD, Janicki JS, Lu B et al (2019) Regulation of cardiac mast cell maturation and function by the neurokinin-1 receptor in the fibrotic heart. Sci Rep 9(1):11004PubMedPubMedCentralCrossRef Widiapradja A, Manteufel EJ, Dehlin HM, Pena J, Goldspink PH, Sharma A, Kolb LL, Imig JD, Janicki JS, Lu B et al (2019) Regulation of cardiac mast cell maturation and function by the neurokinin-1 receptor in the fibrotic heart. Sci Rep 9(1):11004PubMedPubMedCentralCrossRef
21.
22.
Zurück zum Zitat Patella V, de Crescenzo G, Lamparter-Schummert B, De Rosa G, Adt M, Marone G (1997) B L-S, G DR, Adt M, G M: Increased cardiac mast cell density and mediator release in patients with dilated cardiomyopathy. Inflamm Res 46(1):S31–S32PubMedCrossRef Patella V, de Crescenzo G, Lamparter-Schummert B, De Rosa G, Adt M, Marone G (1997) B L-S, G DR, Adt M, G M: Increased cardiac mast cell density and mediator release in patients with dilated cardiomyopathy. Inflamm Res 46(1):S31–S32PubMedCrossRef
23.
Zurück zum Zitat Marone G, Patella V (1995) de CG, Genovese A, Adt M: Human heart mast cells in anaphylaxis and cardiovascular disease. Int Arch Allergy Immunol 107(1–3):72–75PubMedCrossRef Marone G, Patella V (1995) de CG, Genovese A, Adt M: Human heart mast cells in anaphylaxis and cardiovascular disease. Int Arch Allergy Immunol 107(1–3):72–75PubMedCrossRef
24.
Zurück zum Zitat Patella V, Marino I, Lamparter B, Arbustini E, Adt M, Marone G (1995) Human heart mast cells. Isolation, purification, ultrastructure, and immunologic characterization. J Immunol 154(6):2855–2865 Patella V, Marino I, Lamparter B, Arbustini E, Adt M, Marone G (1995) Human heart mast cells. Isolation, purification, ultrastructure, and immunologic characterization. J Immunol 154(6):2855–2865
25.
Zurück zum Zitat Ingason AB, Mechmet F, Atacho DAM, Steingrímsson E, Petersen PH (2019) Distribution of mast cells within the mouse heart and its dependency on Mitf. Mol Immunol 105:9–15PubMedCrossRef Ingason AB, Mechmet F, Atacho DAM, Steingrímsson E, Petersen PH (2019) Distribution of mast cells within the mouse heart and its dependency on Mitf. Mol Immunol 105:9–15PubMedCrossRef
27.
Zurück zum Zitat Morrey C, Brazin J, Seyedi N, Corti F, Silver RB, Levi R (2010) Interaction between sensory C-fibers and cardiac mast cells in ischemia/reperfusion: activation of a local renin-angiotensin system culminating in severe arrhythmic dysfunction. J Pharmacol Exp Ther 335(1):76–84PubMedPubMedCentralCrossRef Morrey C, Brazin J, Seyedi N, Corti F, Silver RB, Levi R (2010) Interaction between sensory C-fibers and cardiac mast cells in ischemia/reperfusion: activation of a local renin-angiotensin system culminating in severe arrhythmic dysfunction. J Pharmacol Exp Ther 335(1):76–84PubMedPubMedCentralCrossRef
28.
Zurück zum Zitat Silver RB, Reid AC, Mackins CJ, Askwith T, Schaefer U, Herzlinger D, Levi R (2004) Mast cells: a unique source of renin. Proc Natl Acad Sci USA 101(37):13607–13612PubMedPubMedCentralCrossRef Silver RB, Reid AC, Mackins CJ, Askwith T, Schaefer U, Herzlinger D, Levi R (2004) Mast cells: a unique source of renin. Proc Natl Acad Sci USA 101(37):13607–13612PubMedPubMedCentralCrossRef
29.
Zurück zum Zitat Arizono N, Matsuda S, Hattori T, Kojima Y, Maeda T, Galli SJ (1990) Anatomical variation in mast cell nerve associations in the rat small intestine, heart, lung, and skin. Similarities of distances between neural processes and mast cells, eosinophils, or plasma cells in the jejunal lamina propria. Lab Invest 62(5):626–634 Arizono N, Matsuda S, Hattori T, Kojima Y, Maeda T, Galli SJ (1990) Anatomical variation in mast cell nerve associations in the rat small intestine, heart, lung, and skin. Similarities of distances between neural processes and mast cells, eosinophils, or plasma cells in the jejunal lamina propria. Lab Invest 62(5):626–634
30.
Zurück zum Zitat Brower GL, Janicki JS (2005) Pharmacologic inhibition of mast cell degranulation prevents left ventricular remodeling induced by chronic volume overload in rats. J Cardiac Fail 11(7):548–556CrossRef Brower GL, Janicki JS (2005) Pharmacologic inhibition of mast cell degranulation prevents left ventricular remodeling induced by chronic volume overload in rats. J Cardiac Fail 11(7):548–556CrossRef
31.
Zurück zum Zitat Stewart JA, Wei CC, Brower GL, Rynders PE, Hankes GH, Dillon AR, Lucchesi PA, Janicki JS, Dell’Italia LJ (2003) Cardiac mast cell- and chymase-mediated matrix metalloproteinase activity and left ventricular remodeling in mitral regurgitation in the dog. J Mol Cell Cardiol 35(3):311–319PubMedCrossRef Stewart JA, Wei CC, Brower GL, Rynders PE, Hankes GH, Dillon AR, Lucchesi PA, Janicki JS, Dell’Italia LJ (2003) Cardiac mast cell- and chymase-mediated matrix metalloproteinase activity and left ventricular remodeling in mitral regurgitation in the dog. J Mol Cell Cardiol 35(3):311–319PubMedCrossRef
32.
Zurück zum Zitat Zhang W, Chancey AL, Tzeng HP, Zhou Z, Lavine KJ, Gao F, Sivasubramanian N, Barger PM, Mann DL (2011) The development of myocardial fibrosis in transgenic mice with targeted overexpression of tumor necrosis factor requires mast cell-fibroblast interactions. Circulation 124(19):2106–2116PubMedPubMedCentralCrossRef Zhang W, Chancey AL, Tzeng HP, Zhou Z, Lavine KJ, Gao F, Sivasubramanian N, Barger PM, Mann DL (2011) The development of myocardial fibrosis in transgenic mice with targeted overexpression of tumor necrosis factor requires mast cell-fibroblast interactions. Circulation 124(19):2106–2116PubMedPubMedCentralCrossRef
33.
Zurück zum Zitat Hara M, Ono K, Hwang MW, Iwasaki A, Okada M, Nakatani K, Sasayama S, Matsumori A (2002) Evidence for a role of mast cells in the evolution to congestive heart failure. J Exp Med 195(3):375–381PubMedPubMedCentralCrossRef Hara M, Ono K, Hwang MW, Iwasaki A, Okada M, Nakatani K, Sasayama S, Matsumori A (2002) Evidence for a role of mast cells in the evolution to congestive heart failure. J Exp Med 195(3):375–381PubMedPubMedCentralCrossRef
34.
Zurück zum Zitat Li QY, Raza-Ahmad A, MacAulay MA, Lalonde LD, Rowden G, Trethewey E, Dean S (1992) The relationship of mast cells and their secreted products to the volume of fibrosis in posttransplant hearts. Transplantation 53(5):1047–1051PubMedCrossRef Li QY, Raza-Ahmad A, MacAulay MA, Lalonde LD, Rowden G, Trethewey E, Dean S (1992) The relationship of mast cells and their secreted products to the volume of fibrosis in posttransplant hearts. Transplantation 53(5):1047–1051PubMedCrossRef
35.
Zurück zum Zitat Zweifel M, Hirsiger H, Matozan K, Welle M, Schaffner T, Mohacsi P (2002) Mast cells in ongoing acute rejection: increase in number and expression of a different phenotype in rat heart transplants. Transplantation 73(11):1707–1716PubMedCrossRef Zweifel M, Hirsiger H, Matozan K, Welle M, Schaffner T, Mohacsi P (2002) Mast cells in ongoing acute rejection: increase in number and expression of a different phenotype in rat heart transplants. Transplantation 73(11):1707–1716PubMedCrossRef
36.
Zurück zum Zitat He A, Fang W, Zhao K, Wang Y, Li J, Yang C, Benadjaoud F, Shi GP (2019) Mast cell-deficiency protects mice from streptozotocin-induced diabetic cardiomyopathy. Translational research : the journal of laboratory and clinical medicine 208:1–14CrossRef He A, Fang W, Zhao K, Wang Y, Li J, Yang C, Benadjaoud F, Shi GP (2019) Mast cell-deficiency protects mice from streptozotocin-induced diabetic cardiomyopathy. Translational research : the journal of laboratory and clinical medicine 208:1–14CrossRef
37.
Zurück zum Zitat Huang ZG, Jin Q, Fan M, Cong XL, Han SF, Gao H, Shan Y (2013) Myocardial remodeling in diabetic cardiomyopathy associated with cardiac mast cell activation. PLoS One 8(3):e60827 Huang ZG, Jin Q, Fan M, Cong XL, Han SF, Gao H, Shan Y (2013) Myocardial remodeling in diabetic cardiomyopathy associated with cardiac mast cell activation. PLoS One 8(3):e60827
38.
Zurück zum Zitat Palaniyandi SS, Watanabe K, Ma M, Tachikawa H, Kodama M, Aizawa Y (2005) Involvement of mast cells in the development of fibrosis in rats with postmyocarditis dilated cardiomyopathy. Biol Pharm Bull 28(11):2128–2132CrossRef Palaniyandi SS, Watanabe K, Ma M, Tachikawa H, Kodama M, Aizawa Y (2005) Involvement of mast cells in the development of fibrosis in rats with postmyocarditis dilated cardiomyopathy. Biol Pharm Bull 28(11):2128–2132CrossRef
39.
Zurück zum Zitat Janicki JS, Brower GL, Levick SP (2015) The emerging prominence of the cardiac mast cell as a potent mediator of adverse myocardial remodeling. Methods in molecular biology (Clifton, NJ) 1220:121–139CrossRef Janicki JS, Brower GL, Levick SP (2015) The emerging prominence of the cardiac mast cell as a potent mediator of adverse myocardial remodeling. Methods in molecular biology (Clifton, NJ) 1220:121–139CrossRef
40.
Zurück zum Zitat Levick SP, Melendez GC, Plante E, McLarty JL, Brower GL, Janicki JS (2011) Cardiac mast cells: the centrepiece in adverse myocardial remodelling. Cardiovasc Res 89(1):12–19PubMedCrossRef Levick SP, Melendez GC, Plante E, McLarty JL, Brower GL, Janicki JS (2011) Cardiac mast cells: the centrepiece in adverse myocardial remodelling. Cardiovasc Res 89(1):12–19PubMedCrossRef
41.
Zurück zum Zitat Levick SP, Widiapradja A (2018) Mast cells: key contributors to cardiac fibrosis. Int J Mol Sci 19(1) Levick SP, Widiapradja A (2018) Mast cells: key contributors to cardiac fibrosis. Int J Mol Sci 19(1)
42.
Zurück zum Zitat Li J, Jubair S, Levick SP, Janicki JS (2016) The autocrine role of tryptase in pressure overload-induced mast cell activation, chymase release and cardiac fibrosis. IJC Metab Endocr 10:16–23PubMedCrossRef Li J, Jubair S, Levick SP, Janicki JS (2016) The autocrine role of tryptase in pressure overload-induced mast cell activation, chymase release and cardiac fibrosis. IJC Metab Endocr 10:16–23PubMedCrossRef
43.
Zurück zum Zitat McLarty JL, Melendez GC, Brower GL, Janicki JS, Levick SP (2011) Tryptase/protease-activated receptor 2 interactions induce selective mitogen-activated protein kinase signaling and collagen synthesis by cardiac fibroblasts. Hypertension (Dallas, Tex: 1979) 58(2):264–270 McLarty JL, Melendez GC, Brower GL, Janicki JS, Levick SP (2011) Tryptase/protease-activated receptor 2 interactions induce selective mitogen-activated protein kinase signaling and collagen synthesis by cardiac fibroblasts. Hypertension (Dallas, Tex: 1979) 58(2):264–270
44.
Zurück zum Zitat Akasu M, Urata H, Kinoshita A, Sasaguri M, Ideishi M, Arakawa K (1998) Differences in Tissue Angiotensin IIûForming Pathways by Species and Organs In Vitro. Hypertension (Dallas, Tex : 1979) 1998, 32(3):514–520 Akasu M, Urata H, Kinoshita A, Sasaguri M, Ideishi M, Arakawa K (1998) Differences in Tissue Angiotensin IIûForming Pathways by Species and Organs In Vitro. Hypertension (Dallas, Tex : 1979) 1998, 32(3):514–520
45.
Zurück zum Zitat Akgul A, Skrabal CA, Thompson LO, Loebe M, Lafuente JA, Noon GP, Youker KA (2004) Role of mast cells and their mediators in failing myocardium under mechanical ventricular support. J Heart Lung Transplant 23(6):709–715PubMedCrossRef Akgul A, Skrabal CA, Thompson LO, Loebe M, Lafuente JA, Noon GP, Youker KA (2004) Role of mast cells and their mediators in failing myocardium under mechanical ventricular support. J Heart Lung Transplant 23(6):709–715PubMedCrossRef
46.
Zurück zum Zitat Jenne DE, Tschopp J (1991) Angiotensin II-forming heart chymase is a mast-cell-specific enzyme. In: Biochem J vol 276, pp 567–568 Jenne DE, Tschopp J (1991) Angiotensin II-forming heart chymase is a mast-cell-specific enzyme. In: Biochem J vol 276,  pp 567–568
47.
Zurück zum Zitat Frangogiannis NG, Burns AR, Michael LH, Entman ML (1999) Histochemical and morphological characteristics of canine cardiac mast cells. Histochem J 31(4):221–229PubMedCrossRef Frangogiannis NG, Burns AR, Michael LH, Entman ML (1999) Histochemical and morphological characteristics of canine cardiac mast cells. Histochem J 31(4):221–229PubMedCrossRef
48.
Zurück zum Zitat Jin D, Takai S, Yamada M, Sakaguchi M, Yao Y, Miyazaki M (2001) Possible roles of cardiac chymase after myocardial infarction in hamster hearts. Jpn J Pharmacol 86(2):203–214PubMedCrossRef Jin D, Takai S, Yamada M, Sakaguchi M, Yao Y, Miyazaki M (2001) Possible roles of cardiac chymase after myocardial infarction in hamster hearts. Jpn J Pharmacol 86(2):203–214PubMedCrossRef
49.
Zurück zum Zitat Kanemitsu H, Takai S, Tsuneyoshi H, Nishina T, Yoshikawa K, Miyazaki M, Ikeda T, Komeda M (2006) Chymase inhibition prevents cardiac fibrosis and dysfunction after myocardial infarction in rats. Hypertens Res 29(1):57–64PubMedCrossRef Kanemitsu H, Takai S, Tsuneyoshi H, Nishina T, Yoshikawa K, Miyazaki M, Ikeda T, Komeda M (2006) Chymase inhibition prevents cardiac fibrosis and dysfunction after myocardial infarction in rats. Hypertens Res 29(1):57–64PubMedCrossRef
50.
Zurück zum Zitat Kanemitsu H, Takai S, Tsuneyoshi H, Yoshikawa E, Nishina T, Miyazaki M, Ikeda T, Komeda M (2008) Chronic chymase inhibition preserves cardiac function after left ventricular repair in rats. Eur J Cardiothorac Surg 33(1):25–31PubMedCrossRef Kanemitsu H, Takai S, Tsuneyoshi H, Yoshikawa E, Nishina T, Miyazaki M, Ikeda T, Komeda M (2008) Chronic chymase inhibition preserves cardiac function after left ventricular repair in rats. Eur J Cardiothorac Surg 33(1):25–31PubMedCrossRef
51.
Zurück zum Zitat Kitaura-Inenaga K, Hara M, Higuchi K, Yamamoto K, Yamaki A, Ono K, Nakano A, Kinoshita M, Sasayama S, Matsumori A (2003) Gene expression of cardiac mast cell chymase and tryptase in a murine model of heart failure caused by viral myocarditis. Circ J 67(10):881–884PubMedCrossRef Kitaura-Inenaga K, Hara M, Higuchi K, Yamamoto K, Yamaki A, Ono K, Nakano A, Kinoshita M, Sasayama S, Matsumori A (2003) Gene expression of cardiac mast cell chymase and tryptase in a murine model of heart failure caused by viral myocarditis. Circ J 67(10):881–884PubMedCrossRef
52.
Zurück zum Zitat Matsumoto C, Hayashi T, Kitada K, Yamashita C, Miyamura M, Mori T, Ukimura A, Ohkita M, Jin D, Takai S et al (2009) Chymase plays an important role in left ventricular remodeling induced by intermittent hypoxia in mice. Hypertension (Dallas, Tex: 1979) 54(1):164–171 Matsumoto C, Hayashi T, Kitada K, Yamashita C, Miyamura M, Mori T, Ukimura A, Ohkita M, Jin D, Takai S et al (2009) Chymase plays an important role in left ventricular remodeling induced by intermittent hypoxia in mice. Hypertension (Dallas, Tex: 1979) 54(1):164–171
53.
Zurück zum Zitat Oyamada S, Bianchi C, Takai S, Chu LM, Sellke FW (2011) Chymase inhibition reduces infarction and matrix metalloproteinase-9 activation and attenuates inflammation and fibrosis after acute myocardial ischemia/reperfusion. J Pharmacol Exp Ther 339(1):143–151PubMedCrossRef Oyamada S, Bianchi C, Takai S, Chu LM, Sellke FW (2011) Chymase inhibition reduces infarction and matrix metalloproteinase-9 activation and attenuates inflammation and fibrosis after acute myocardial ischemia/reperfusion. J Pharmacol Exp Ther 339(1):143–151PubMedCrossRef
54.
Zurück zum Zitat Shiota NJD, Takai S, Kawamura T, Koyama M, Nakamura N, Miyazakai M (1997) Chymase is activated in the hamster heart following ventricular fibrosis during the chronic stage of hypertension. FEBS Lett 406:301–304PubMedCrossRef Shiota NJD, Takai S, Kawamura T, Koyama M, Nakamura N, Miyazakai M (1997) Chymase is activated in the hamster heart following ventricular fibrosis during the chronic stage of hypertension. FEBS Lett 406:301–304PubMedCrossRef
55.
Zurück zum Zitat Somasundaram P, Ren G, Nagar H, Kraemer D, Mendoza L, Michael LH, Caughey GH, Entman ML, Frangogiannis NG (2005) Mast cell tryptase may modulate endothelial cell phenotype in healing myocardial infarcts. J Pathol 205(1):102–111PubMedPubMedCentralCrossRef Somasundaram P, Ren G, Nagar H, Kraemer D, Mendoza L, Michael LH, Caughey GH, Entman ML, Frangogiannis NG (2005) Mast cell tryptase may modulate endothelial cell phenotype in healing myocardial infarcts. J Pathol 205(1):102–111PubMedPubMedCentralCrossRef
56.
Zurück zum Zitat Takai S, Jin D, Muramatsu M, Okamoto Y, Miyazaki M (2004) Therapeutic applications of chymase inhibitors in cardiovascular diseases and fibrosis. Eur J Pharmacol 501(1–3):1–8PubMedCrossRef Takai S, Jin D, Muramatsu M, Okamoto Y, Miyazaki M (2004) Therapeutic applications of chymase inhibitors in cardiovascular diseases and fibrosis. Eur J Pharmacol 501(1–3):1–8PubMedCrossRef
57.
Zurück zum Zitat Takai S, Jin D, Sakaguchi M, Katayama S, Muramatsu M, Sakaguchi M, Matsumura E, Kim S, Miyazaki M (2003) A novel chymase inhibitor, 4-[1-([bis-(4-methyl-phenyl)-methyl]-carbamoyl)3-(2-ethoxy-benzyl)-4-oxo-azetidin e-2-yloxy]-benzoic acid (BCEAB), suppressed cardiac fibrosis in cardiomyopathic hamsters. J Pharmacol Exp Ther 305(1):17–23PubMedCrossRef Takai S, Jin D, Sakaguchi M, Katayama S, Muramatsu M, Sakaguchi M, Matsumura E, Kim S, Miyazaki M (2003) A novel chymase inhibitor, 4-[1-([bis-(4-methyl-phenyl)-methyl]-carbamoyl)3-(2-ethoxy-benzyl)-4-oxo-azetidin e-2-yloxy]-benzoic acid (BCEAB), suppressed cardiac fibrosis in cardiomyopathic hamsters. J Pharmacol Exp Ther 305(1):17–23PubMedCrossRef
58.
Zurück zum Zitat Zhao XY, Zhao LY, Zheng QS, Su JL, Guan H, Shang FJ, Niu XL, He YP, Lu XL (2008) Chymase induces profibrotic response via transforming growth factor-beta 1/Smad activation in rat cardiac fibroblasts. Mol Cell Biochem 310(1–2):159–166PubMedCrossRef Zhao XY, Zhao LY, Zheng QS, Su JL, Guan H, Shang FJ, Niu XL, He YP, Lu XL (2008) Chymase induces profibrotic response via transforming growth factor-beta 1/Smad activation in rat cardiac fibroblasts. Mol Cell Biochem 310(1–2):159–166PubMedCrossRef
59.
Zurück zum Zitat Triggiani M, Genovese A, Vigorito C, Marone G (1985) Histamine and human heart. Int Arch Allergy Appl Immunol 77(1–2):174–176PubMedCrossRef Triggiani M, Genovese A, Vigorito C, Marone G (1985) Histamine and human heart. Int Arch Allergy Appl Immunol 77(1–2):174–176PubMedCrossRef
61.
Zurück zum Zitat Bristow MR, Kantrowitz NE, Harrison WD, Minobe WA, Sageman WS, Billingham ME (1983) Mediation of subacute anthracycline cardiotoxicity in rabbits by cardiac histamine release. J Cardiovasc Pharmacol 5(6):913–919PubMedCrossRef Bristow MR, Kantrowitz NE, Harrison WD, Minobe WA, Sageman WS, Billingham ME (1983) Mediation of subacute anthracycline cardiotoxicity in rabbits by cardiac histamine release. J Cardiovasc Pharmacol 5(6):913–919PubMedCrossRef
62.
Zurück zum Zitat Decorti G, Candussio L, Klugmann FB, Strohmayer A, Mucci MP, Mosco A, Baldini L (1997) Adriamycin-induced histamine release from heart tissue in vitro. Cancer Chemother Pharmacol 40(4):363–366PubMedCrossRef Decorti G, Candussio L, Klugmann FB, Strohmayer A, Mucci MP, Mosco A, Baldini L (1997) Adriamycin-induced histamine release from heart tissue in vitro. Cancer Chemother Pharmacol 40(4):363–366PubMedCrossRef
63.
Zurück zum Zitat Kondru SK, Potnuri AG, Allakonda L, Konduri P (2018) Histamine 2 receptor antagonism elicits protection against doxorubicin-induced cardiotoxicity in rodent model. Mol Cell Biochem 441(1–2):77–88PubMedCrossRef Kondru SK, Potnuri AG, Allakonda L, Konduri P (2018) Histamine 2 receptor antagonism elicits protection against doxorubicin-induced cardiotoxicity in rodent model. Mol Cell Biochem 441(1–2):77–88PubMedCrossRef
64.
Zurück zum Zitat Zdravkovic V, Pantovic S, Rosic G, Tomic-Lucic A, Zdravkovic N, Colic M, Obradovic Z, Rosic M (2011) Histamine blood concentration in ischemic heart disease patients. J Biomed Biotechnol 2011:315709 Zdravkovic V, Pantovic S, Rosic G, Tomic-Lucic A, Zdravkovic N, Colic M, Obradovic Z, Rosic M (2011) Histamine blood concentration in ischemic heart disease patients. J Biomed Biotechnol 2011:315709
65.
Zurück zum Zitat Asanuma H, Minamino T, Ogai A, Kim J, Asakura M, Komamura K, Sanada S, Fujita M, Hirata A, Wakeno M et al (2006) Blockade of histamine H2 receptors protects the heart against ischemia and reperfusion injury in dogs. J Mol Cell Cardiol 40(5):666–674PubMedCrossRef Asanuma H, Minamino T, Ogai A, Kim J, Asakura M, Komamura K, Sanada S, Fujita M, Hirata A, Wakeno M et al (2006) Blockade of histamine H2 receptors protects the heart against ischemia and reperfusion injury in dogs. J Mol Cell Cardiol 40(5):666–674PubMedCrossRef
66.
Zurück zum Zitat Valen G, Kaszaki J, Szabo I, Nagy S, Vaage J (1994) Histamine release and its effects in ischaemia-reperfusion injury of the isolated rat heart. Acta Physiol Scand 150(4):413–424PubMedCrossRef Valen G, Kaszaki J, Szabo I, Nagy S, Vaage J (1994) Histamine release and its effects in ischaemia-reperfusion injury of the isolated rat heart. Acta Physiol Scand 150(4):413–424PubMedCrossRef
67.
Zurück zum Zitat Potnuri AG, Allakonda L, Appavoo A, Saheera S, Nair RR (2018) Association of histamine with hypertension-induced cardiac remodeling and reduction of hypertrophy with the histamine-2-receptor antagonist famotidine compared with the beta-blocker metoprolol. Hypertension research : official journal of the Japanese Society of Hypertension 41(12):1023–1035CrossRef Potnuri AG, Allakonda L, Appavoo A, Saheera S, Nair RR (2018) Association of histamine with hypertension-induced cardiac remodeling and reduction of hypertrophy with the histamine-2-receptor antagonist famotidine compared with the beta-blocker metoprolol. Hypertension research : official journal of the Japanese Society of Hypertension 41(12):1023–1035CrossRef
68.
Zurück zum Zitat Kantrowitz NE, Bristow MR, Minobe WA, Billingham ME, Harrison DC (1982) Histamine-mediated myocardial damage in rabbits. J Mol Cell Cardiol 14(9):551–555PubMedCrossRef Kantrowitz NE, Bristow MR, Minobe WA, Billingham ME, Harrison DC (1982) Histamine-mediated myocardial damage in rabbits. J Mol Cell Cardiol 14(9):551–555PubMedCrossRef
69.
Zurück zum Zitat He GH, Cai WK, Meng JR, Ma X, Zhang F, Lu J, Xu GL (2015) Relation of polymorphism of the histidine decarboxylase gene to chronic heart failure in Han Chinese. Am J Cardiol 115(11):1555–1562PubMedCrossRef He GH, Cai WK, Meng JR, Ma X, Zhang F, Lu J, Xu GL (2015) Relation of polymorphism of the histidine decarboxylase gene to chronic heart failure in Han Chinese. Am J Cardiol 115(11):1555–1562PubMedCrossRef
70.
Zurück zum Zitat Walter M, Stark H (2012) Histamine receptor subtypes: a century of rational drug design. Front Biosci (Schol Ed) 4:461–488CrossRef Walter M, Stark H (2012) Histamine receptor subtypes: a century of rational drug design. Front Biosci (Schol Ed) 4:461–488CrossRef
71.
Zurück zum Zitat Monczor F, Fernandez N (2016) Current knowledge and perspectives on histamine H1 and H2 receptor pharmacology: functional selectivity, receptor crosstalk, and repositioning of classic histaminergic ligands. Mol Pharmacol 90(5):640–648PubMedCrossRef Monczor F, Fernandez N (2016) Current knowledge and perspectives on histamine H1 and H2 receptor pharmacology: functional selectivity, receptor crosstalk, and repositioning of classic histaminergic ligands. Mol Pharmacol 90(5):640–648PubMedCrossRef
72.
Zurück zum Zitat Simons FE, Simons KJ (2011) Histamine and H1-antihistamines: celebrating a century of progress. J Allergy Clin Immunol 128(6):1139-1150.e1134PubMedCrossRef Simons FE, Simons KJ (2011) Histamine and H1-antihistamines: celebrating a century of progress. J Allergy Clin Immunol 128(6):1139-1150.e1134PubMedCrossRef
73.
Zurück zum Zitat Mills JG, Wood JR (1989) The pharmacology of histamine H2-receptor antagonists. Methods Find Exp Clin Pharmacol 11(Suppl 1):87–95PubMed Mills JG, Wood JR (1989) The pharmacology of histamine H2-receptor antagonists. Methods Find Exp Clin Pharmacol 11(Suppl 1):87–95PubMed
74.
Zurück zum Zitat Schunack W (1989) Pharmacology of H2-receptor antagonists: an overview. J Int Med Res 17(Suppl 1):9a–16aPubMed Schunack W (1989) Pharmacology of H2-receptor antagonists: an overview. J Int Med Res 17(Suppl 1):9a–16aPubMed
75.
Zurück zum Zitat Micallef S, Stark H, Sasse A (2013) Polymorphisms and genetic linkage of histamine receptors. Life Sci 93(15):487–494PubMedCrossRef Micallef S, Stark H, Sasse A (2013) Polymorphisms and genetic linkage of histamine receptors. Life Sci 93(15):487–494PubMedCrossRef
76.
Zurück zum Zitat Tanimoto A, Sasaguri Y, Ohtsu H (2006) Histamine network in atherosclerosis. Trends Cardiovasc Med 16(8):280–284PubMedCrossRef Tanimoto A, Sasaguri Y, Ohtsu H (2006) Histamine network in atherosclerosis. Trends Cardiovasc Med 16(8):280–284PubMedCrossRef
77.
Zurück zum Zitat Matsuda N, Jesmin S, Takahashi Y, Hatta E, Kobayashi M, Matsuyama K, Kawakami N, Sakuma I, Gando S, Fukui H et al (2004) Histamine H1 and H2 receptor gene and protein levels are differentially expressed in the hearts of rodents and humans. J Pharmacol Exp Ther 309(2):786–795PubMedCrossRef Matsuda N, Jesmin S, Takahashi Y, Hatta E, Kobayashi M, Matsuyama K, Kawakami N, Sakuma I, Gando S, Fukui H et al (2004) Histamine H1 and H2 receptor gene and protein levels are differentially expressed in the hearts of rodents and humans. J Pharmacol Exp Ther 309(2):786–795PubMedCrossRef
78.
Zurück zum Zitat Nault MA, Milne B, Parlow JL (2002) Effects of the selective H1 and H2 histamine receptor antagonists loratadine and ranitidine on autonomic control of the heart. Anesthesiology 96(2):336–341PubMedCrossRef Nault MA, Milne B, Parlow JL (2002) Effects of the selective H1 and H2 histamine receptor antagonists loratadine and ranitidine on autonomic control of the heart. Anesthesiology 96(2):336–341PubMedCrossRef
79.
Zurück zum Zitat Felix SB, Baumann G, Helmus S, Sattelberger U (1988) The role of histamine in cardiac anaphylaxis; characterization of histaminergic H1- and H2-receptor effects. Basic Res Cardiol 83(5):531–539PubMedCrossRef Felix SB, Baumann G, Helmus S, Sattelberger U (1988) The role of histamine in cardiac anaphylaxis; characterization of histaminergic H1- and H2-receptor effects. Basic Res Cardiol 83(5):531–539PubMedCrossRef
80.
Zurück zum Zitat Assem ES (1989) Anaphylactic reactions affecting the human heart. Agents Actions 27(1–2):142–145PubMedCrossRef Assem ES (1989) Anaphylactic reactions affecting the human heart. Agents Actions 27(1–2):142–145PubMedCrossRef
81.
Zurück zum Zitat Denizot Y, Boudet J, Burtin C, Marro I, Benveniste J (1990) Monoclonal IgE-mediated cardiac hypersensitivity reactions in the guinea-pig. Agents Actions 29(3–4):167–171PubMedCrossRef Denizot Y, Boudet J, Burtin C, Marro I, Benveniste J (1990) Monoclonal IgE-mediated cardiac hypersensitivity reactions in the guinea-pig. Agents Actions 29(3–4):167–171PubMedCrossRef
82.
Zurück zum Zitat Levi R, Zavecz JH, Ovary Z (1978) IgE-mediated cardiac hypersensitivity reactions. An experimental model. Int Arch Allergy Appl Immunol 57(6):529–534 Levi R, Zavecz JH, Ovary Z (1978) IgE-mediated cardiac hypersensitivity reactions. An experimental model. Int Arch Allergy Appl Immunol 57(6):529–534
83.
Zurück zum Zitat Silva Machado FR, Assem ES, Ezeamuzie CI (1985) Cardiac anaphylaxis: the role of different mediators. Part I: histamine Allergol Immunopathol (Madr ) 13(3):259–272 Silva Machado FR, Assem ES, Ezeamuzie CI (1985) Cardiac anaphylaxis: the role of different mediators. Part I: histamine Allergol Immunopathol (Madr ) 13(3):259–272
84.
Zurück zum Zitat Gebbia N, Flandina C, Leto G, Tumminello FM, Sanguedolce R, Candiloro V, Gagliano M, Rausa L (1987) The role of histamine in doxorubicin and teniposide-induced cardiotoxicity in dog and mouse. Tumori 73(3):279–287PubMedCrossRef Gebbia N, Flandina C, Leto G, Tumminello FM, Sanguedolce R, Candiloro V, Gagliano M, Rausa L (1987) The role of histamine in doxorubicin and teniposide-induced cardiotoxicity in dog and mouse. Tumori 73(3):279–287PubMedCrossRef
85.
Zurück zum Zitat Bristow MR, Cubicciotti R, Ginsburg R, Stinson EB, Johnson C (1982) Histamine-mediated adenylate cyclase stimulation in human myocardium. Mol Pharmacol 21(3):671–679PubMed Bristow MR, Cubicciotti R, Ginsburg R, Stinson EB, Johnson C (1982) Histamine-mediated adenylate cyclase stimulation in human myocardium. Mol Pharmacol 21(3):671–679PubMed
86.
Zurück zum Zitat Tozzi CA, Dorrell SG, Merrill GF (1985) Evidence of histamine-induced myocardial ischaemia: reversal by chlorpheniramine and potentiation by atherosclerosis. Cardiovasc Res 19(12):744–753PubMedCrossRef Tozzi CA, Dorrell SG, Merrill GF (1985) Evidence of histamine-induced myocardial ischaemia: reversal by chlorpheniramine and potentiation by atherosclerosis. Cardiovasc Res 19(12):744–753PubMedCrossRef
87.
Zurück zum Zitat Ginsburg R, Bristow MR, Kantrowitz N, Baim DS, Harrison DC (1981) Histamine provocation of clinical coronary artery spasm: implications concerning pathogenesis of variant angina pectoris. Am Heart J 102(5):819–822PubMedCrossRef Ginsburg R, Bristow MR, Kantrowitz N, Baim DS, Harrison DC (1981) Histamine provocation of clinical coronary artery spasm: implications concerning pathogenesis of variant angina pectoris. Am Heart J 102(5):819–822PubMedCrossRef
88.
Zurück zum Zitat Shimokawa H, Tomoike H, Nabeyama S, Yamamoto H, Nakamura M (1985) Histamine-induced spasm not significantly modulated by prostanoids in a swine model of coronary artery spasm. J Am Coll Cardiol 6(2):321–327PubMedCrossRef Shimokawa H, Tomoike H, Nabeyama S, Yamamoto H, Nakamura M (1985) Histamine-induced spasm not significantly modulated by prostanoids in a swine model of coronary artery spasm. J Am Coll Cardiol 6(2):321–327PubMedCrossRef
89.
Zurück zum Zitat Kounis NG, Zavras GM (1991) Histamine-induced coronary artery spasm: the concept of allergic angina. Br J Clin Pract 45(2):121–128PubMed Kounis NG, Zavras GM (1991) Histamine-induced coronary artery spasm: the concept of allergic angina. Br J Clin Pract 45(2):121–128PubMed
90.
Zurück zum Zitat Kounis NG (2006) Kounis syndrome (allergic angina and allergic myocardial infarction): a natural paradigm? Int J Cardiol 110(1):7–14PubMedCrossRef Kounis NG (2006) Kounis syndrome (allergic angina and allergic myocardial infarction): a natural paradigm? Int J Cardiol 110(1):7–14PubMedCrossRef
91.
Zurück zum Zitat Erdogan O, Altun A, Gazi S, Ozbay G (2004) Loratidine improves ischemic parameters of exercise stress test in patients with acute myocardial infarction. Am Heart J 148(6):e24 Erdogan O, Altun A, Gazi S, Ozbay G (2004) Loratidine improves ischemic parameters of exercise stress test in patients with acute myocardial infarction. Am Heart J 148(6):e24
92.
Zurück zum Zitat Miyazawa N, Watanabe S, Matsuda A, Kondo K, Hashimoto H, Umemura K, Nakashima M (1998) Role of histamine H1 and H2 receptor antagonists in the prevention of intimal thickening. Eur J Pharmacol 362(1):53–59PubMedCrossRef Miyazawa N, Watanabe S, Matsuda A, Kondo K, Hashimoto H, Umemura K, Nakashima M (1998) Role of histamine H1 and H2 receptor antagonists in the prevention of intimal thickening. Eur J Pharmacol 362(1):53–59PubMedCrossRef
93.
Zurück zum Zitat Rozenberg I, Sluka SH, Rohrer L, Hofmann J, Becher B, Akhmedov A, Soliz J, Mocharla P, Borén J, Johansen P et al (2010) Histamine H1 receptor promotes atherosclerotic lesion formation by increasing vascular permeability for low-density lipoproteins. Arterioscler Thromb Vasc Biol 30(5):923–930PubMedCrossRef Rozenberg I, Sluka SH, Rohrer L, Hofmann J, Becher B, Akhmedov A, Soliz J, Mocharla P, Borén J, Johansen P et al (2010) Histamine H1 receptor promotes atherosclerotic lesion formation by increasing vascular permeability for low-density lipoproteins. Arterioscler Thromb Vasc Biol 30(5):923–930PubMedCrossRef
94.
Zurück zum Zitat Harman D (1962) Atherosclerosis; inhibiting effect of an antihistaminic drug, chlorpheniramine. Circ Res 11:277–282PubMedCrossRef Harman D (1962) Atherosclerosis; inhibiting effect of an antihistaminic drug, chlorpheniramine. Circ Res 11:277–282PubMedCrossRef
95.
Zurück zum Zitat Clejan S, Japa S, Clemetson C, Hasabnis SS, David O, Talano JV (2002) Blood histamine is associated with coronary artery disease, cardiac events and severity of inflammation and atherosclerosis. J Cell Mol Med 6(4):583–592PubMedPubMedCentralCrossRef Clejan S, Japa S, Clemetson C, Hasabnis SS, David O, Talano JV (2002) Blood histamine is associated with coronary artery disease, cardiac events and severity of inflammation and atherosclerosis. J Cell Mol Med 6(4):583–592PubMedPubMedCentralCrossRef
96.
Zurück zum Zitat Takagishi T, Sasaguri Y, Nakano R, Arima N, Tanimoto A, Fukui H, Morimatsu M (1995) Expression of the histamine H1 receptor gene in relation to atherosclerosis. Am J Pathol 146(4):981–988PubMedPubMedCentral Takagishi T, Sasaguri Y, Nakano R, Arima N, Tanimoto A, Fukui H, Morimatsu M (1995) Expression of the histamine H1 receptor gene in relation to atherosclerosis. Am J Pathol 146(4):981–988PubMedPubMedCentral
97.
Zurück zum Zitat Zhou Y, Gao C, Wang H, Liu L, Huang Z, Fa X (2018) Histamine H1 type receptor antagonist loratadine ameliorates oxidized LDL induced endothelial dysfunction. Biomed Pharmacother 106:1448–1453 Zhou Y, Gao C, Wang H, Liu L, Huang Z, Fa X (2018) Histamine H1 type receptor antagonist loratadine ameliorates oxidized LDL induced endothelial dysfunction. Biomed Pharmacother 106:1448–1453
98.
Zurück zum Zitat Jacobson BC, Ferris TG, Shea TL, Mahlis EM, Lee TH, Wang TC (2003) Who is using chronic acid suppression therapy and why? Am J Gastroenterol 98(1):51–58PubMedCrossRef Jacobson BC, Ferris TG, Shea TL, Mahlis EM, Lee TH, Wang TC (2003) Who is using chronic acid suppression therapy and why? Am J Gastroenterol 98(1):51–58PubMedCrossRef
99.
Zurück zum Zitat Reinhardt D, Schmidt U, Brodde OE, Schümann HJ (1977) H1 - and H2-receptor mediated responses to histamine on contractility and cyclic AMP of atrial and papillary muscles from guinea-pig hearts. Agents Actions 7(1):1–12PubMedCrossRef Reinhardt D, Schmidt U, Brodde OE, Schümann HJ (1977) H1 - and H2-receptor mediated responses to histamine on contractility and cyclic AMP of atrial and papillary muscles from guinea-pig hearts. Agents Actions 7(1):1–12PubMedCrossRef
100.
Zurück zum Zitat Gergs U, Bernhardt G, Buchwalow IB, Edler H, Fröba J, Keller M, Kirchhefer U, Köhler F, Mißlinger N, Wache H et al (2019) Initial characterization of transgenic mice overexpressing human histamine H(2) receptors. J Pharmacol Exp Ther 369(1):129–141PubMedCrossRef Gergs U, Bernhardt G, Buchwalow IB, Edler H, Fröba J, Keller M, Kirchhefer U, Köhler F, Mißlinger N, Wache H et al (2019) Initial characterization of transgenic mice overexpressing human histamine H(2) receptors. J Pharmacol Exp Ther 369(1):129–141PubMedCrossRef
101.
Zurück zum Zitat Gergs U, Kirchhefer U, Bergmann F, Künstler B, Mißlinger N, Au B, Mahnkopf M, Wache H, Neumann J (2020) Characterization of stressed transgenic mice overexpressing H(2)-histamine receptors in the heart. J Pharmacol Exp Ther 374(3):479–488PubMedCrossRef Gergs U, Kirchhefer U, Bergmann F, Künstler B, Mißlinger N, Au B, Mahnkopf M, Wache H, Neumann J (2020) Characterization of stressed transgenic mice overexpressing H(2)-histamine receptors in the heart. J Pharmacol Exp Ther 374(3):479–488PubMedCrossRef
102.
Zurück zum Zitat Takahama H, Asanuma H, Sanada S, Fujita M, Sasaki H, Wakeno M, Kim J, Asakura M, Takashima S, Minamino T et al (2010) A histamine H2 receptor blocker ameliorates development of heart failure in dogs independently of β-adrenergic receptor blockade. Basic Res Cardiol 105(6):787–794PubMedCrossRef Takahama H, Asanuma H, Sanada S, Fujita M, Sasaki H, Wakeno M, Kim J, Asakura M, Takashima S, Minamino T et al (2010) A histamine H2 receptor blocker ameliorates development of heart failure in dogs independently of β-adrenergic receptor blockade. Basic Res Cardiol 105(6):787–794PubMedCrossRef
103.
Zurück zum Zitat Zeng Z, Shen L, Li X, Luo T, Wei X, Zhang J, Cao S, Huang X, Fukushima Y, Bin J et al (2014) Disruption of histamine H2 receptor slows heart failure progression through reducing myocardial apoptosis and fibrosis. Clin Sci (London, England: 1979) 127(7):435–448 Zeng Z, Shen L, Li X, Luo T, Wei X, Zhang J, Cao S, Huang X, Fukushima Y, Bin J et al (2014) Disruption of histamine H2 receptor slows heart failure progression through reducing myocardial apoptosis and fibrosis. Clin Sci (London, England: 1979) 127(7):435–448
104.
Zurück zum Zitat Kingwell BA (2000) Nitric oxide-mediated metabolic regulation during exercise: effects of training in health and cardiovascular disease. FASEB journal : official publication of the Federation of American Societies for Experimental Biology 14(12):1685–1696CrossRef Kingwell BA (2000) Nitric oxide-mediated metabolic regulation during exercise: effects of training in health and cardiovascular disease. FASEB journal : official publication of the Federation of American Societies for Experimental Biology 14(12):1685–1696CrossRef
105.
Zurück zum Zitat Luo T, Chen B, Zhao Z, He N, Zeng Z, Wu B, Fukushima Y, Dai M, Huang Q, Xu D et al (2013) Histamine H2 receptor activation exacerbates myocardial ischemia/reperfusion injury by disturbing mitochondrial and endothelial function. Basic Res Cardiol 108(3):342PubMedCrossRef Luo T, Chen B, Zhao Z, He N, Zeng Z, Wu B, Fukushima Y, Dai M, Huang Q, Xu D et al (2013) Histamine H2 receptor activation exacerbates myocardial ischemia/reperfusion injury by disturbing mitochondrial and endothelial function. Basic Res Cardiol 108(3):342PubMedCrossRef
106.
Zurück zum Zitat Potnuri AG, Allakonda L, Saheera S (2020) Involvement of histamine 2 receptor in alpha 1 adrenoceptor mediated cardiac hypertrophy and oxidative stress in H9c2 cardio myoblasts. J Cardiovasc Transl Res Potnuri AG, Allakonda L, Saheera S (2020) Involvement of histamine 2 receptor in alpha 1 adrenoceptor mediated cardiac hypertrophy and oxidative stress in H9c2 cardio myoblasts. J Cardiovasc Transl Res
107.
Zurück zum Zitat Kim J, Washio T, Yamagishi M, Yasumura Y, Nakatani S, Hashimura K, Hanatani A, Komamura K, Miyatake K, Kitamura S et al (2004) A novel data mining approach to the identification of effective drugs or combinations for targeted endpoints–application to chronic heart failure as a new form of evidence-based medicine. Cardiovasc Drugs Ther 18(6):483–489PubMedCrossRef Kim J, Washio T, Yamagishi M, Yasumura Y, Nakatani S, Hashimura K, Hanatani A, Komamura K, Miyatake K, Kitamura S et al (2004) A novel data mining approach to the identification of effective drugs or combinations for targeted endpoints–application to chronic heart failure as a new form of evidence-based medicine. Cardiovasc Drugs Ther 18(6):483–489PubMedCrossRef
108.
Zurück zum Zitat Kim J, Ogai A, Nakatani S, Hashimura K, Kanzaki H, Komamura K, Asakura M, Asanuma H, Kitamura S, Tomoike H et al (2006) Impact of blockade of histamine H2 receptors on chronic heart failure revealed by retrospective and prospective randomized studies. J Am Coll Cardiol 48(7):1378–1384PubMedCrossRef Kim J, Ogai A, Nakatani S, Hashimura K, Kanzaki H, Komamura K, Asakura M, Asanuma H, Kitamura S, Tomoike H et al (2006) Impact of blockade of histamine H2 receptors on chronic heart failure revealed by retrospective and prospective randomized studies. J Am Coll Cardiol 48(7):1378–1384PubMedCrossRef
109.
Zurück zum Zitat Bild DE, Bluemke DA, Burke GL, Detrano R, Diez Roux AV, Folsom AR, Greenland P, Jacob DR Jr, Kronmal R, Liu K et al (2002) Multi-ethnic study of atherosclerosis: objectives and design. Am J Epidemiol 156(9):871–881PubMedCrossRef Bild DE, Bluemke DA, Burke GL, Detrano R, Diez Roux AV, Folsom AR, Greenland P, Jacob DR Jr, Kronmal R, Liu K et al (2002) Multi-ethnic study of atherosclerosis: objectives and design. Am J Epidemiol 156(9):871–881PubMedCrossRef
110.
Zurück zum Zitat Leary PJ, Tedford RJ, Bluemke DA, Bristow MR, Heckbert SR, Kawut SM, Krieger EV, Lima JA, Masri CS, Ralph DD et al (2016) Histamine H2 receptor antagonists, left ventricular morphology, and heart failure risk: the MESA study. J Am Coll Cardiol 67(13):1544–1552PubMedPubMedCentralCrossRef Leary PJ, Tedford RJ, Bluemke DA, Bristow MR, Heckbert SR, Kawut SM, Krieger EV, Lima JA, Masri CS, Ralph DD et al (2016) Histamine H2 receptor antagonists, left ventricular morphology, and heart failure risk: the MESA study. J Am Coll Cardiol 67(13):1544–1552PubMedPubMedCentralCrossRef
111.
Zurück zum Zitat Adelborg K, Sundbøll J, Schmidt M, Bøtker HE, Weiss NS, Pedersen L, Sørensen HT (2018) Use of histamine H(2) receptor antagonists and outcomes in patients with heart failure: a nationwide population-based cohort study. Clin Epidemiol 10:521–530PubMedPubMedCentralCrossRef Adelborg K, Sundbøll J, Schmidt M, Bøtker HE, Weiss NS, Pedersen L, Sørensen HT (2018) Use of histamine H(2) receptor antagonists and outcomes in patients with heart failure: a nationwide population-based cohort study. Clin Epidemiol 10:521–530PubMedPubMedCentralCrossRef
112.
Zurück zum Zitat Leary PJ, Barr RG, Bluemke DA, Bristow MR, Kronmal RA, Lima JA, Ralph DD, Ventetuolo CE, Kawut SM (2014) H2 receptor antagonists and right ventricular morphology: the MESA right ventricle study. Ann Am Thorac Soc 11(9):1379–1386PubMedPubMedCentralCrossRef Leary PJ, Barr RG, Bluemke DA, Bristow MR, Kronmal RA, Lima JA, Ralph DD, Ventetuolo CE, Kawut SM (2014) H2 receptor antagonists and right ventricular morphology: the MESA right ventricle study. Ann Am Thorac Soc 11(9):1379–1386PubMedPubMedCentralCrossRef
113.
Zurück zum Zitat Yoshihisa A, Takiguchi M, Kanno Y, Sato A, Yokokawa T, Miura S, Abe S, Misaka T, Sato T, Suzuki S et al (2017) Associations of acid suppressive therapy with cardiac mortality in heart failure patients. J Am Heart Assoc 6(5) Yoshihisa A, Takiguchi M, Kanno Y, Sato A, Yokokawa T, Miura S, Abe S, Misaka T, Sato T, Suzuki S et al (2017) Associations of acid suppressive therapy with cardiac mortality in heart failure patients. J Am Heart Assoc 6(5)
115.
Zurück zum Zitat Kirch W, Halabi A, Linde M, Santos SR, Ohnhaus EE (1989) Negative effects of famotidine on cardiac performance assessed by noninvasive hemodynamic measurements. Gastroenterology 96(6):1388–1392PubMedCrossRef Kirch W, Halabi A, Linde M, Santos SR, Ohnhaus EE (1989) Negative effects of famotidine on cardiac performance assessed by noninvasive hemodynamic measurements. Gastroenterology 96(6):1388–1392PubMedCrossRef
116.
Zurück zum Zitat Hinrichsen H, Halabi A, Kirch W (1990) Hemodynamic effects of different H2-receptor antagonists. Clin Pharmacol Ther 48(3):302–308PubMedCrossRef Hinrichsen H, Halabi A, Kirch W (1990) Hemodynamic effects of different H2-receptor antagonists. Clin Pharmacol Ther 48(3):302–308PubMedCrossRef
117.
Zurück zum Zitat Halabi A, Nokhodian A, Kirch W (1992) Haemodynamic effects of roxatidine, an H2-receptor antagonist. Clin Investig 70(2):118–121PubMedCrossRef Halabi A, Nokhodian A, Kirch W (1992) Haemodynamic effects of roxatidine, an H2-receptor antagonist. Clin Investig 70(2):118–121PubMedCrossRef
118.
Zurück zum Zitat Kirch W, Halabi A, Hinrichsen H (1992) Hemodynamic effects of quinidine and famotidine in patients with congestive heart failure. Clin Pharmacol Ther 51(3):325–333PubMedCrossRef Kirch W, Halabi A, Hinrichsen H (1992) Hemodynamic effects of quinidine and famotidine in patients with congestive heart failure. Clin Pharmacol Ther 51(3):325–333PubMedCrossRef
119.
Zurück zum Zitat Lucas BD Jr, Williams MA, Mohiuddin SM, LaMadrid LJ, Schroeder LJ, Hilleman DE (1998) Effect of oral H2-receptor antagonists on left ventricular systolic function and exercise capacity in patients with chronic stable heart failure. Pharmacotherapy 18(4):824–830PubMed Lucas BD Jr, Williams MA, Mohiuddin SM, LaMadrid LJ, Schroeder LJ, Hilleman DE (1998) Effect of oral H2-receptor antagonists on left ventricular systolic function and exercise capacity in patients with chronic stable heart failure. Pharmacotherapy 18(4):824–830PubMed
120.
Zurück zum Zitat Endou M, Poli E, Levi R (1994) Histamine H3-receptor signaling in the heart: possible involvement of Gi/Go proteins and N-type Ca++ channels. J Pharmacol Exp Ther 269(1):221–229PubMed Endou M, Poli E, Levi R (1994) Histamine H3-receptor signaling in the heart: possible involvement of Gi/Go proteins and N-type Ca++ channels. J Pharmacol Exp Ther 269(1):221–229PubMed
121.
Zurück zum Zitat Mazenot C, Ribuot C, Durand A, Joulin Y, Demenge P, Godin-Ribuot D (1999) In vivo demonstration of H3-histaminergic inhibition of cardiac sympathetic stimulation by R-alpha-methyl-histamine and its prodrug BP 2.94 in the dog. Br J Pharmacol 126(1):264–268 Mazenot C, Ribuot C, Durand A, Joulin Y, Demenge P, Godin-Ribuot D (1999) In vivo demonstration of H3-histaminergic inhibition of cardiac sympathetic stimulation by R-alpha-methyl-histamine and its prodrug BP 2.94 in the dog. Br J Pharmacol 126(1):264–268
122.
Zurück zum Zitat Imamura M, Poli E, Omoniyi AT, Levi R (1994) Unmasking of activated histamine H3-receptors in myocardial ischemia: their role as regulators of exocytotic norepinephrine release. J Pharmacol Exp Ther 271(3):1259–1266PubMed Imamura M, Poli E, Omoniyi AT, Levi R (1994) Unmasking of activated histamine H3-receptors in myocardial ischemia: their role as regulators of exocytotic norepinephrine release. J Pharmacol Exp Ther 271(3):1259–1266PubMed
123.
Zurück zum Zitat Chrusch C, Sharma S, Unruh H, Bautista E, Duke K, Becker A, Kepron W, Mink SN (1999) Histamine H3 receptor blockade improves cardiac function in canine anaphylaxis. Am J Respir Crit Care Med 160(4):1142–1149PubMedCrossRef Chrusch C, Sharma S, Unruh H, Bautista E, Duke K, Becker A, Kepron W, Mink SN (1999) Histamine H3 receptor blockade improves cardiac function in canine anaphylaxis. Am J Respir Crit Care Med 160(4):1142–1149PubMedCrossRef
124.
Zurück zum Zitat Hatta E, Yasuda K, Levi R (1997) Activation of histamine H3 receptors inhibits carrier-mediated norepinephrine release in a human model of protracted myocardial ischemia. J Pharmacol Exp Ther 283(2):494–500PubMed Hatta E, Yasuda K, Levi R (1997) Activation of histamine H3 receptors inhibits carrier-mediated norepinephrine release in a human model of protracted myocardial ischemia. J Pharmacol Exp Ther 283(2):494–500PubMed
125.
Zurück zum Zitat Imamura M, Lander HM, Levi R (1996) Activation of histamine H3-receptors inhibits carrier-mediated norepinephrine release during protracted myocardial ischemia. Comparison with adenosine A1-receptors and alpha2-adrenoceptors. Circ Res 78(3):475–481 Imamura M, Lander HM, Levi R (1996) Activation of histamine H3-receptors inhibits carrier-mediated norepinephrine release during protracted myocardial ischemia. Comparison with adenosine A1-receptors and alpha2-adrenoceptors. Circ Res 78(3):475–481
126.
Zurück zum Zitat Imamura M, Seyedi N, Lander HM, Levi R (1995) Functional identification of histamine H3-receptors in the human heart. Circ Res 77(1):206–210PubMedCrossRef Imamura M, Seyedi N, Lander HM, Levi R (1995) Functional identification of histamine H3-receptors in the human heart. Circ Res 77(1):206–210PubMedCrossRef
127.
Zurück zum Zitat Böhm M, Maack C (2000) Treatment of heart failure with beta-blockers. Mechanisms and results. Basic Res Cardiol 95(1):I15–24 Böhm M, Maack C (2000) Treatment of heart failure with beta-blockers. Mechanisms and results. Basic Res Cardiol 95(1):I15–24
128.
Zurück zum Zitat Silver RB, Poonwasi KS, Seyedi N, Wilson SJ, Lovenberg TW, Levi R (2002) Decreased intracellular calcium mediates the histamine H3-receptor-induced attenuation of norepinephrine exocytosis from cardiac sympathetic nerve endings. Proc Natl Acad Sci USA 99(1):501–506PubMedCrossRef Silver RB, Poonwasi KS, Seyedi N, Wilson SJ, Lovenberg TW, Levi R (2002) Decreased intracellular calcium mediates the histamine H3-receptor-induced attenuation of norepinephrine exocytosis from cardiac sympathetic nerve endings. Proc Natl Acad Sci USA 99(1):501–506PubMedCrossRef
129.
Zurück zum Zitat Seyedi N, Mackins CJ, Machida T, Reid AC, Silver RB, Levi R (2005) Histamine H3-receptor-induced attenuation of norepinephrine exocytosis: a decreased protein kinase a activity mediates a reduction in intracellular calcium. J Pharmacol Exp Ther 312(1):272–280PubMedCrossRef Seyedi N, Mackins CJ, Machida T, Reid AC, Silver RB, Levi R (2005) Histamine H3-receptor-induced attenuation of norepinephrine exocytosis: a decreased protein kinase a activity mediates a reduction in intracellular calcium. J Pharmacol Exp Ther 312(1):272–280PubMedCrossRef
130.
Zurück zum Zitat Levi R, Seyedi N, Schaefer U, Estephan R, Mackins CJ, Tyler E, Silver RB (2007) Histamine H3-receptor signaling in cardiac sympathetic nerves: Identification of a novel MAPK-PLA2-COX-PGE2-EP3R pathway. Biochem Pharmacol 73(8):1146–1156PubMedPubMedCentralCrossRef Levi R, Seyedi N, Schaefer U, Estephan R, Mackins CJ, Tyler E, Silver RB (2007) Histamine H3-receptor signaling in cardiac sympathetic nerves: Identification of a novel MAPK-PLA2-COX-PGE2-EP3R pathway. Biochem Pharmacol 73(8):1146–1156PubMedPubMedCentralCrossRef
131.
Zurück zum Zitat Hashikawa-Hobara N, Chan NY, Levi R (2012) Histamine 3 receptor activation reduces the expression of neuronal angiotensin II type 1 receptors in the heart. J Pharmacol Exp Ther 340(1):185–191PubMedPubMedCentralCrossRef Hashikawa-Hobara N, Chan NY, Levi R (2012) Histamine 3 receptor activation reduces the expression of neuronal angiotensin II type 1 receptors in the heart. J Pharmacol Exp Ther 340(1):185–191PubMedPubMedCentralCrossRef
132.
Zurück zum Zitat Morisset S, Sasse A, Gbahou F, Héron A, Ligneau X, Tardivel-Lacombe J, Schwartz JC, Arrang JM (2001) The rat H3 receptor: gene organization and multiple isoforms. Biochem Biophys Res Commun 280(1):75–80PubMedCrossRef Morisset S, Sasse A, Gbahou F, Héron A, Ligneau X, Tardivel-Lacombe J, Schwartz JC, Arrang JM (2001) The rat H3 receptor: gene organization and multiple isoforms. Biochem Biophys Res Commun 280(1):75–80PubMedCrossRef
133.
Zurück zum Zitat McCaffrey SL, Lim G, Bullock M, Ksparian AO, Clifton-Bligh R, Campbell WB, Widiapradja A, Levick SP (2020) The histamine 3 receptor is expressed in the heart and its activation opposes adverse cardiac remodeling in the angiotensin II mouse model. Int J Mol Sci 21(24) McCaffrey SL, Lim G, Bullock M, Ksparian AO, Clifton-Bligh R, Campbell WB, Widiapradja A, Levick SP (2020) The histamine 3 receptor is expressed in the heart and its activation opposes adverse cardiac remodeling in the angiotensin II mouse model. Int J Mol Sci 21(24)
134.
Zurück zum Zitat Piera L, Olczak S, Kun T, Galdyszynska M, Ciosek J, Szymanski J, Drobnik J (2019) Disruption of histamine/H3 receptor signal reduces collagen deposition in cultures scar myofibroblasts. J Physiol Pharmacol 70(2) Piera L, Olczak S, Kun T, Galdyszynska M, Ciosek J, Szymanski J, Drobnik J (2019) Disruption of histamine/H3 receptor signal reduces collagen deposition in cultures scar myofibroblasts. J Physiol Pharmacol 70(2)
135.
Zurück zum Zitat Henegar JR. Brower GL, Kabour A, Janicki JS (1995) Catecholamine response to chronic ANG II infusion and its role in myocyte and coronary vascular damage. In: Am J Physiol. Edited by GL B, A K, JS J, vol. 269; H1564-H1569 Henegar JR. Brower GL, Kabour A, Janicki JS (1995) Catecholamine response to chronic ANG II infusion and its role in myocyte and coronary vascular damage. In: Am J Physiol. Edited by GL B, A K, JS J, vol. 269; H1564-H1569
136.
Zurück zum Zitat Henegar JR, Schwartz DD, Janicki JS (1998) ANG II-related myocardial damage: role of cardiac sympathetic catecholamines and beta-receptor regulation. In: Am J Physiol. Edited by DD S, JS J, vol. 275; H534-H541 Henegar JR, Schwartz DD, Janicki JS (1998) ANG II-related myocardial damage: role of cardiac sympathetic catecholamines and beta-receptor regulation. In: Am J Physiol. Edited by DD S, JS J, vol. 275; H534-H541
137.
Zurück zum Zitat Kabour A, Henegar JR, Janicki JS (1994) Angiotensin II (AII)-induced myocyte necrosis: role of the AII receptor. J Cardiovasc Pharmacol 23(4):547–553PubMedCrossRef Kabour A, Henegar JR, Janicki JS (1994) Angiotensin II (AII)-induced myocyte necrosis: role of the AII receptor. J Cardiovasc Pharmacol 23(4):547–553PubMedCrossRef
138.
Zurück zum Zitat Perlini S, Palladini G, Ferrero I, Tozzi R, Fallarini S, Facoetti A, Nano R, Clari F, Busca G, Fogari R et al (2005) Sympathectomy or doxazosin, but not propranolol, blunt myocardial interstitial fibrosis in pressure-overload hypertrophy. Hypertension (Dallas, Tex: 1979) 46(5):1213–1218 Perlini S, Palladini G, Ferrero I, Tozzi R, Fallarini S, Facoetti A, Nano R, Clari F, Busca G, Fogari R et al (2005) Sympathectomy or doxazosin, but not propranolol, blunt myocardial interstitial fibrosis in pressure-overload hypertrophy. Hypertension (Dallas, Tex: 1979) 46(5):1213–1218
139.
Zurück zum Zitat Lameris TW, de Zeeuw S, Duncker DJ, Alberts G, Boomsma F, Verdouw PD, van den Meiracker AH (2002) Exogenous angiotensin II does not facilitate norepinephrine release in the heart. Hypertension (Dallas, Tex: 1979) 40(4):491–497 Lameris TW, de Zeeuw S, Duncker DJ, Alberts G, Boomsma F, Verdouw PD, van den Meiracker AH (2002) Exogenous angiotensin II does not facilitate norepinephrine release in the heart. Hypertension (Dallas, Tex: 1979) 40(4):491–497
140.
Zurück zum Zitat Yadav CH, Najmi AK, Akhtar M, Khanam R (2015) Cardioprotective role of H3R agonist imetit on isoproterenol-induced hemodynamic changes and oxidative stress in rats. Toxicol Mech Methods 25(4):235–240PubMedCrossRef Yadav CH, Najmi AK, Akhtar M, Khanam R (2015) Cardioprotective role of H3R agonist imetit on isoproterenol-induced hemodynamic changes and oxidative stress in rats. Toxicol Mech Methods 25(4):235–240PubMedCrossRef
141.
Zurück zum Zitat Chen Y, Paavola J, Stegajev V, Stark H, Chazot PL, Wen JG, Konttinen YT (2015) Activation of histamine H3 receptor decreased cytoplasmic Ca(2+) imaging during electrical stimulation in the skeletal myotubes. Eur J Pharmacol 754:173–178PubMedCrossRef Chen Y, Paavola J, Stegajev V, Stark H, Chazot PL, Wen JG, Konttinen YT (2015) Activation of histamine H3 receptor decreased cytoplasmic Ca(2+) imaging during electrical stimulation in the skeletal myotubes. Eur J Pharmacol 754:173–178PubMedCrossRef
142.
Zurück zum Zitat Dehlin HM, Levick SP (2014) Substance P in heart failure: the good and the bad. Int J Cardiol 170(3):270–277PubMedCrossRef Dehlin HM, Levick SP (2014) Substance P in heart failure: the good and the bad. Int J Cardiol 170(3):270–277PubMedCrossRef
143.
Zurück zum Zitat Dehlin HM, Manteufel EJ, Monroe AL, Reimer MH Jr, Levick SP (2013) Substance P acting via the neurokinin-1 receptor regulates adverse myocardial remodeling in a rat model of hypertension. Int J Cardiol 168(5):4643–4651PubMedPubMedCentralCrossRef Dehlin HM, Manteufel EJ, Monroe AL, Reimer MH Jr, Levick SP (2013) Substance P acting via the neurokinin-1 receptor regulates adverse myocardial remodeling in a rat model of hypertension. Int J Cardiol 168(5):4643–4651PubMedPubMedCentralCrossRef
144.
Zurück zum Zitat Levick SP, Soto-Pantoja DR, Bi J, Hundley WG, Widiapradja A, Manteufel EJ, Bradshaw TW, Meléndez GC (2019) Doxorubicin-induced myocardial fibrosis involves the neurokinin-1 Receptor and direct effects on cardiac fibroblasts. Heart Lung Circ 28(10):1598–1605PubMedCrossRef Levick SP, Soto-Pantoja DR, Bi J, Hundley WG, Widiapradja A, Manteufel EJ, Bradshaw TW, Meléndez GC (2019) Doxorubicin-induced myocardial fibrosis involves the neurokinin-1 Receptor and direct effects on cardiac fibroblasts. Heart Lung Circ 28(10):1598–1605PubMedCrossRef
145.
Zurück zum Zitat Kramer JH, Phillips TM, Weglicki WB (1997) Magnesium-deficiency-enhanced post-ischemic myocardial injury is reduced by substance P receptor blockade. J Mol Cell Cardiol 29(1):97–110PubMedCrossRef Kramer JH, Phillips TM, Weglicki WB (1997) Magnesium-deficiency-enhanced post-ischemic myocardial injury is reduced by substance P receptor blockade. J Mol Cell Cardiol 29(1):97–110PubMedCrossRef
146.
Zurück zum Zitat Mak IT, Chmielinska JJ, Kramer JH, Spurney CF, Weglicki WB (2011) Loss of neutral endopeptidase activity contributes to neutrophil activation and cardiac dysfunction during chronic hypomagnesemia: Protection by substance P receptor blockade. Exp Clin Cardiol 16(4):121–124PubMedPubMedCentral Mak IT, Chmielinska JJ, Kramer JH, Spurney CF, Weglicki WB (2011) Loss of neutral endopeptidase activity contributes to neutrophil activation and cardiac dysfunction during chronic hypomagnesemia: Protection by substance P receptor blockade. Exp Clin Cardiol 16(4):121–124PubMedPubMedCentral
147.
Zurück zum Zitat Mak IT, Kramer JH, Chmielinska JJ, Spurney CF, Weglicki WB (2015) EGFR-TKI, erlotinib, causes hypomagnesemia, oxidative stress, and cardiac dysfunction: attenuation by NK-1 receptor blockade. J Cardiovasc Pharmacol 65(1):54–61PubMedPubMedCentralCrossRef Mak IT, Kramer JH, Chmielinska JJ, Spurney CF, Weglicki WB (2015) EGFR-TKI, erlotinib, causes hypomagnesemia, oxidative stress, and cardiac dysfunction: attenuation by NK-1 receptor blockade. J Cardiovasc Pharmacol 65(1):54–61PubMedPubMedCentralCrossRef
148.
Zurück zum Zitat Weglicki WB, Mak IT, Phillips TM (1994) Blockade of cardiac inflammation in Mg2+ deficiency by substance P receptor inhibition. Circ Res 74(5):1009–1013PubMedCrossRef Weglicki WB, Mak IT, Phillips TM (1994) Blockade of cardiac inflammation in Mg2+ deficiency by substance P receptor inhibition. Circ Res 74(5):1009–1013PubMedCrossRef
149.
Zurück zum Zitat D’Souza M, Garza MA, Xie M, Weinstock J, Xiang Q, Robinson P (2007) Substance P is associated with heart enlargement and apoptosis in murine dilated cardiomyopathy induced by Taenia crassiceps infection. J Parasitol 93(5):1121–1127PubMedCrossRef D’Souza M, Garza MA, Xie M, Weinstock J, Xiang Q, Robinson P (2007) Substance P is associated with heart enlargement and apoptosis in murine dilated cardiomyopathy induced by Taenia crassiceps infection. J Parasitol 93(5):1121–1127PubMedCrossRef
150.
Zurück zum Zitat Robinson P, Garza A, Moore J, Eckols TK, Parti S, Balaji V, Vallejo J, Tweardy DJ (2009) Substance P is required for the pathogenesis of EMCV infection in mice. Int J Clin Exp Med 2(1):76–86PubMedPubMedCentral Robinson P, Garza A, Moore J, Eckols TK, Parti S, Balaji V, Vallejo J, Tweardy DJ (2009) Substance P is required for the pathogenesis of EMCV infection in mice. Int J Clin Exp Med 2(1):76–86PubMedPubMedCentral
151.
Zurück zum Zitat Robinson P, Taffet GE, Engineer N, Khumbatta M, Firozgary B, Reynolds C, Pham T, Bulsara T, Firozgary G (2015) Substance P receptor antagonism: a potential novel treatment option for viral-myocarditis. BioMed Res Int 2015:645153 Robinson P, Taffet GE, Engineer N, Khumbatta M, Firozgary B, Reynolds C, Pham T, Bulsara T, Firozgary G (2015) Substance P receptor antagonism: a potential novel treatment option for viral-myocarditis. BioMed Res Int 2015:645153
152.
Zurück zum Zitat He GH, Cai WK, Zhang JB, Ma CY, Yan F, Lu J, Xu GL (2016) Associations of polymorphisms in HRH2, HRH3, DAO, and HNMT genes with risk of chronic heart failure. Biomed Res Int 2016:1208476PubMedPubMedCentralCrossRef He GH, Cai WK, Zhang JB, Ma CY, Yan F, Lu J, Xu GL (2016) Associations of polymorphisms in HRH2, HRH3, DAO, and HNMT genes with risk of chronic heart failure. Biomed Res Int 2016:1208476PubMedPubMedCentralCrossRef
153.
Zurück zum Zitat Noguchi K, Ishida J, Kim JD, Muromachi N, Kako K, Mizukami H, Lu W, Ishimaru T, Kawasaki S, Kaneko S et al (2020) Histamine receptor agonist alleviates severe cardiorenal damages by eliciting anti-inflammatory programming. Proc Natl Acad Sci USA 117(6):3150–3156PubMedPubMedCentralCrossRef Noguchi K, Ishida J, Kim JD, Muromachi N, Kako K, Mizukami H, Lu W, Ishimaru T, Kawasaki S, Kaneko S et al (2020) Histamine receptor agonist alleviates severe cardiorenal damages by eliciting anti-inflammatory programming. Proc Natl Acad Sci USA 117(6):3150–3156PubMedPubMedCentralCrossRef
154.
Zurück zum Zitat Pinacho-García M, Marichal-Cancino BA, Villalón CM (2016) Further evidence for the role of histamine H3, but not H1, H2 or H4, receptors in immepip-induced inhibition of the rat cardioaccelerator sympathetic outflow. Eur J Pharmacol 773:85–92PubMedCrossRef Pinacho-García M, Marichal-Cancino BA, Villalón CM (2016) Further evidence for the role of histamine H3, but not H1, H2 or H4, receptors in immepip-induced inhibition of the rat cardioaccelerator sympathetic outflow. Eur J Pharmacol 773:85–92PubMedCrossRef
155.
Zurück zum Zitat Stasiak A, Gola J, Kraszewska K, Mussur M, Kobos J, Mazurek U, Stark H, Fogel WA (2018) Experimental autoimmune myocarditis in rats and therapeutic histamine H1 - H4 receptor inhibition. J Physiol Pharmacol 69(6) Stasiak A, Gola J, Kraszewska K, Mussur M, Kobos J, Mazurek U, Stark H, Fogel WA (2018) Experimental autoimmune myocarditis in rats and therapeutic histamine H1 - H4 receptor inhibition. J Physiol Pharmacol 69(6)
156.
Zurück zum Zitat Durante M, Sgambellone S, Lanzi C, Nardini P, Pini A, Moroni F, Masini E, Lucarini L (2019) Effects of PARP-1 deficiency and histamine H(4) receptor inhibition in an inflammatory model of lung fibrosis in mice. Front Pharmacol 10:525PubMedPubMedCentralCrossRef Durante M, Sgambellone S, Lanzi C, Nardini P, Pini A, Moroni F, Masini E, Lucarini L (2019) Effects of PARP-1 deficiency and histamine H(4) receptor inhibition in an inflammatory model of lung fibrosis in mice. Front Pharmacol 10:525PubMedPubMedCentralCrossRef
157.
Zurück zum Zitat Rossbach K, Wahle K, Bruer G, Brehm R, Langeheine M, Rode K, Schaper-Gerhardt K, Gutzmer R, Werfel T, Kietzmann M et al (2020) Histamine 2 receptor agonism and histamine 4 receptor antagonism ameliorate inflammation in a model of psoriasis. Acta dermato-venereologica 100(19):adv00342 Rossbach K, Wahle K, Bruer G, Brehm R, Langeheine M, Rode K, Schaper-Gerhardt K, Gutzmer R, Werfel T, Kietzmann M et al (2020) Histamine 2 receptor agonism and histamine 4 receptor antagonism ameliorate inflammation in a model of psoriasis. Acta dermato-venereologica 100(19):adv00342
158.
Zurück zum Zitat Wechsler JB, Szabo A, Hsu CL, Krier-Burris RA, Schroeder HA, Wang MY, Carter RG, Velez TE, Aguiniga LM, Brown JB et al (2018) Histamine drives severity of innate inflammation via histamine 4 receptor in murine experimental colitis. Mucosal Immunol 11(3):861–870PubMedPubMedCentralCrossRef Wechsler JB, Szabo A, Hsu CL, Krier-Burris RA, Schroeder HA, Wang MY, Carter RG, Velez TE, Aguiniga LM, Brown JB et al (2018) Histamine drives severity of innate inflammation via histamine 4 receptor in murine experimental colitis. Mucosal Immunol 11(3):861–870PubMedPubMedCentralCrossRef
159.
Zurück zum Zitat He GH, Xu GL, Cai WK, Zhang J (2016) Is histamine H(2) receptor a real promising target for prevention or treatment of heart failure? J Am Coll Cardiol 68(18):2029PubMedCrossRef He GH, Xu GL, Cai WK, Zhang J (2016) Is histamine H(2) receptor a real promising target for prevention or treatment of heart failure? J Am Coll Cardiol 68(18):2029PubMedCrossRef
160.
Zurück zum Zitat Leary PJ, Bristow MR (2016) Reply: Is histamine H(2) receptor a real promising target for prevention or treatment of heart failure? J Am Coll Cardiol 68(18):2029–2030PubMedCrossRef Leary PJ, Bristow MR (2016) Reply: Is histamine H(2) receptor a real promising target for prevention or treatment of heart failure? J Am Coll Cardiol 68(18):2029–2030PubMedCrossRef
Metadaten
Titel
Histamine receptors in heart failure
verfasst von
Scott P. Levick
Publikationsdatum
08.10.2021
Verlag
Springer US
Erschienen in
Heart Failure Reviews / Ausgabe 4/2022
Print ISSN: 1382-4147
Elektronische ISSN: 1573-7322
DOI
https://doi.org/10.1007/s10741-021-10166-x

Weitere Artikel der Ausgabe 4/2022

Heart Failure Reviews 4/2022 Zur Ausgabe

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.